Nintedanib
CAS 656247-17-5
Nintedanib (CAS 656247-17-5) is a pharmaceutical compound with 80 bioactivity targets and 2,737 adverse event associations.
SOURCE
NLM DailyMed
Label records
0
SOURCE
EMBL-EBI ChEMBL
Bioactivity
225
SOURCE
DrugCentral
Adverse signals
2,737
SOURCE
IUPHAR/BPS
PubMed IDs
2
SOURCE
DrugCentral
055904D152D6
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Nintedanib
CAS Number
656247-17-5
UNII
G6HRD2P839
InChIKey
XZXHXSATPCNXJR-ZIADKAODSA-N
ChEMBL ID
CHEMBL3039504
DrugCentral Struct ID
4903
Source Match
DrugCentral (CAS), FDA GSRS (UNII)
SOURCE
EMBL-EBI ChEMBL
80 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| Calcium/calmodulin-dependent protein kinase type II subunit alpha Kinase |
Kd | 5.44 | - | Homo sapiens |
| Serine/threonine-protein kinase 17B Kinase |
Kd | 6.17 | - | Homo sapiens |
| Serine/threonine-protein kinase 10 Kinase |
Kd | 7.06 | - | Homo sapiens |
| Tyrosine-protein kinase JAK3 Kinase |
Kd | 8.09 | - | Homo sapiens |
| Potassium voltage-gated channel subfamily H member 2 Ion channel |
IC50 | 8.59 | - | Homo sapiens |
| Multidrug resistance protein 1 Transporter |
EC50 | 6.56 | - | Homo sapiens |
| Tyrosine-protein kinase Fer Kinase |
Kd | 7.14 | - | Homo sapiens |
| Platelet-derived growth factor receptor beta Kinase |
Kd | 7.82 | - | Homo sapiens |
| Tyrosine-protein kinase ABL1 Kinase |
Kd | 8 | - | Homo sapiens |
| Mast/stem cell growth factor receptor Kit Kinase |
Kd | 8.57 | - | Homo sapiens |
| Breakpoint cluster region protein Kinase |
Kd | 6.52 | - | Homo sapiens |
| Proto-oncogene tyrosine-protein kinase Src Kinase |
Kd | 6.24 | - | Homo sapiens |
| Tyrosine-protein kinase Lck Kinase |
Kd | 8.21 | - | Homo sapiens |
| Tyrosine-protein kinase Yes Kinase |
Kd | 7.1 | - | Homo sapiens |
| Tyrosine-protein kinase Fyn Kinase |
Kd | 6.2 | - | Homo sapiens |
| Ephrin type-A receptor 2 Kinase |
Kd | 5.54 | - | Homo sapiens |
| Receptor-type tyrosine-protein kinase FLT3 Kinase |
Kd | 9.38 | - | Homo sapiens |
| Proto-oncogene tyrosine-protein kinase receptor Ret Kinase |
Kd | 8.02 | - | Homo sapiens |
| Macrophage colony-stimulating factor 1 receptor Kinase |
Kd | 7.32 | - | Homo sapiens |
| Ribosomal protein S6 kinase alpha-3 Kinase |
Kd | 7.19 | - | Homo sapiens |
| Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Kinase |
Kd | 6.59 | - | Homo sapiens |
| Cyclin-dependent kinase 2 Kinase |
Kd | 5.85 | - | Homo sapiens |
| Insulin-like growth factor 1 receptor Kinase |
Kd | 7.21 | - | Homo sapiens |
| Myosin light chain kinase, smooth muscle Kinase |
Kd | 6.54 | - | Homo sapiens |
| Insulin receptor Kinase |
Kd | 7.62 | - | Homo sapiens |
| Death-associated protein kinase 3 Kinase |
Kd | 5.68 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type 1 Kinase |
Kd | 5.23 | - | Homo sapiens |
| Mitogen-activated protein kinase 8 Kinase |
Kd | 6.2 | - | Homo sapiens |
| Fibroblast growth factor receptor 3 Kinase |
Kd | 7.03 | - | Homo sapiens |
| Focal adhesion kinase 1 Kinase |
Kd | 6.68 | - | Homo sapiens |
| Tyrosine-protein kinase HCK Kinase |
Kd | 5.28 | - | Homo sapiens |
| Tyrosine-protein kinase JAK1 Kinase |
Kd | 8.32 | - | Homo sapiens |
| Mitogen-activated protein kinase 10 Kinase |
Kd | 6.57 | - | Homo sapiens |
| Death-associated protein kinase 2 Kinase |
Kd | 5.49 | - | Homo sapiens |
| High affinity nerve growth factor receptor Kinase |
Kd | 8.35 | - | Homo sapiens |
| Tyrosine-protein kinase JAK2 Kinase |
Kd | 7.85 | - | Homo sapiens |
| Myosin light chain kinase 2, skeletal/cardiac muscle Kinase |
Kd | 5.4 | - | Homo sapiens |
| Angiopoietin-1 receptor Kinase |
Kd | 5.85 | - | Homo sapiens |
| AP2-associated protein kinase 1 Kinase |
Kd | 7.2 | - | Homo sapiens |
| Serine/threonine-protein kinase MARK2 Kinase |
Kd | 5.85 | - | Homo sapiens |
| Hepatocyte growth factor receptor Kinase |
Kd | 6.7 | - | Homo sapiens |
| Tyrosine-protein kinase Lyn Kinase |
Kd | 6.03 | - | Homo sapiens |
| Ribosomal protein S6 kinase alpha-2 Kinase |
Kd | 7.24 | - | Homo sapiens |
| 5'-AMP-activated protein kinase catalytic subunit alpha-1 Kinase |
Kd | 7.06 | - | Homo sapiens |
| Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Kinase |
Kd | 6.85 | - | Homo sapiens |
| Serine/threonine-protein kinase PLK4 Kinase |
Kd | 7.28 | - | Homo sapiens |
| Aurora kinase C Kinase |
Kd | 6.72 | - | Homo sapiens |
| Serine/threonine-protein kinase 16 Kinase |
Kd | 7.74 | - | Homo sapiens |
| Dual specificity protein kinase TTK Kinase |
Kd | 7.66 | - | Homo sapiens |
| Abelson tyrosine-protein kinase 2 Kinase |
Kd | 5.7 | - | Homo sapiens |
SOURCE
DrugCentral
80 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Diarrhoea | 2368 | 2529.907 | 10012735 |
| Malignant neoplasm progression | 600 | 897.189 | 10051398 |
| Death | 1056 | 697.303 | 10011906 |
| Decreased appetite | 733 | 645.422 | 10061428 |
| Nausea | 1055 | 397.476 | 10028813 |
| Weight decreased | 594 | 379.28 | 10047895 |
| Pneumothorax | 174 | 311.859 | 10035759 |
| Dyspnoea | 845 | 277.812 | 10013968 |
| Vomiting | 670 | 222.82 | 10047700 |
| Lung transplant | 71 | 197.402 | 10025127 |
| Drug ineffective | 134 | 192.732 | 10013709 |
| Cough | 422 | 173.738 | 10011224 |
| Idiopathic pulmonary fibrosis | 64 | 173.706 | 10021240 |
| Respiratory failure | 243 | 138.317 | 10038695 |
| Drug-induced liver injury | 140 | 131.741 | 10072268 |
| Liver disorder | 152 | 131.153 | 10024670 |
| Abnormal loss of weight | 61 | 120.846 | 10000159 |
| Faeces soft | 59 | 117.611 | 10074859 |
| Productive cough | 154 | 115.529 | 10036790 |
| Pulmonary embolism | 221 | 111.885 | 10037377 |
| Flatulence | 109 | 105.354 | 10016766 |
| Constipation | 301 | 100.186 | 10010774 |
| Pulmonary hypertension | 103 | 93.505 | 10037400 |
| Infusion related reaction | 4 | 90.715 | 10051792 |
| Drug hypersensitivity | 12 | 90.646 | 10013700 |
| Oxygen saturation decreased | 171 | 87.004 | 10033318 |
| Interstitial lung disease | 151 | 85.24 | 10022611 |
| Dyspnoea exertional | 132 | 84.541 | 10013971 |
| Hepatic function abnormal | 116 | 82.804 | 10019670 |
| Pneumonia | 495 | 81.212 | 10035664 |
| Pulmonary function test decreased | 44 | 78.821 | 10061922 |
| Epistaxis | 145 | 76.991 | 10015090 |
| Forced vital capacity decreased | 27 | 75.889 | 10074722 |
| Pneumomediastinum | 33 | 75.72 | 10050184 |
| Toxicity to various agents | 28 | 74.891 | 10070863 |
| Arthropathy | 4 | 74.151 | 10003285 |
| Chronic respiratory failure | 31 | 73.319 | 10009126 |
| Product use issue | 8 | 72.494 | 10076309 |
| Abdominal pain upper | 228 | 72.404 | 10000087 |
| Pain | 127 | 70.557 | 10033371 |
| Lung neoplasm malignant | 72 | 68.113 | 10058467 |
| Joint swelling | 23 | 67.939 | 10023232 |
| Therapeutic product effect decreased | 3 | 65.527 | 10082201 |
| Musculoskeletal stiffness | 3 | 64.912 | 10052904 |
| Treatment failure | 6 | 64.792 | 10066901 |
| Pulmonary fibrosis | 88 | 63.681 | 10037383 |
| Metastases to central nervous system | 54 | 62.698 | 10059282 |
| Completed suicide | 4 | 61.672 | 10010144 |
| Liver function test increased | 77 | 61.376 | 10077692 |
| Gamma-glutamyltransferase increased | 87 | 60.634 | 10017693 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
IUPHAR/BPS
10 interactions
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| fms related receptor tyrosine kinase 4 FLT4 |
Inhibition | 7.889999866485596 pIC50 | 18559524 |
| fibroblast growth factor receptor 1 FGFR1 |
Inhibition | 7.159999847412109 pIC50 | 18559524 |
| fibroblast growth factor receptor 2 FGFR2 |
Inhibition | 7.429999828338623 pIC50 | 18559524 |
| fibroblast growth factor receptor 3 FGFR3 |
Inhibition | 6.96999979019165 pIC50 | 18559524 |
| fibroblast growth factor receptor 4 FGFR4 |
Inhibition | 6.210000038146973 pIC50 | 18559524 |
| fms related receptor tyrosine kinase 1 FLT1 |
Inhibition | 7.510000228881836 pIC50 | 18559524 |
| kinase insert domain receptor KDR |
Inhibition | 7.679999828338623 pIC50 | 18559524 |
| large tumor suppressor kinase 1 LATS1 |
Inhibition | 4.96999979019165 pKd | 29191878 |
| platelet derived growth factor receptor alpha PDGFRA |
Inhibition | 7.230000019073486 pIC50 | 18559524 |
| platelet derived growth factor receptor beta PDGFRB |
Inhibition | 7.190000057220459 pIC50 | 18559524 |
SOURCE
NLM RxNorm
3 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| Nintedanib | 1592737 | SU | MTHSPL |
| NINTEDANIB | 1592737 | SU | MTHSPL |
| nintedanib | 1592737 | IN | RXNORM |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Nintedanib used for in pharmaceutical contexts?
Nintedanib (CAS 656247-17-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Nintedanib?
Nintedanib has 2,737 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Diarrhoea, Malignant neoplasm progression, Death, Decreased appetite, Nausea. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Nintedanib also used in cosmetics?
No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Nintedanib.
What clinical phase is Nintedanib in?
No phase 1-4 clinical development badge is rendered for Nintedanib because the matched compound identifier rows do not contain a max-phase value.
What bioactivity targets are documented for Nintedanib?
Nintedanib has 225 bioactivity rows in this page query. Rendered target entries include Calcium/calmodulin-dependent protein kinase type II subunit alpha, Serine/threonine-protein kinase 17B, Serine/threonine-protein kinase 10, Tyrosine-protein kinase JAK3, Potassium voltage-gated channel subfamily H member 2.